SAN FRANCISCO, Oct. 11 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) announced today that G. Steven Burrill, Founder and Chief Executive Officer, Burrill & Company, and James A. Geraghty, Senior Vice President, Genzyme Corporation, have joined the organization's Board of Directors. The addition of these two new board members rounds out the BVGH Board with a depth of expertise and experience in emerging markets and public-private partnerships.
"Both Steve Burrill and Jim Geraghty are long-standing colleagues in the biotech industry, deeply involved and widely respected," says Carl Feldbaum, Chair of BVGH's Board of Directors. "Their commitment and enthusiasm for biotechnology's increasing role in global health is beyond question. Our Board of Directors, staff, and donors are proud to have them now fully engaged in addressing the neglected diseases of the developing world."
Burrill founded Burrill & Company as a logical extension of his 40+ year involvement in the growth and prosperity of the biotechnology industry. Over the course of his career, Burrill has been an active advisor and catalyst to some of the industry's most well-known companies and transactions. Notably—prior to founding Burrill & Company in 1994—he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.
In addition to his membership on BVGH's Board, Burrill currently serves as Chairman of the Boards of Pharmasset, Abunda Corporation, Foundation for the National Medals of Science and Technology, Vilas County Economic Development Corporation, and the World Council of Ethics. He also serves as Chair of the San Francisco Mayor's Biotech Advisory Committee. He is a member of the Boards of Directors of Catalyst Biosciences, DepoMed, NewBridge, Proventys, Targacept, and XDx. He serves as a member o
|SOURCE BIO Ventures for Global Health|
Copyright©2010 PR Newswire.
All rights reserved